Furthermore, the PPARγ agonists troglitazone, rosiglitazone, as well as pioglitazone, alone or in combination with different therapeutic agents, may not only improve glycemic control or insulin sensitivity, but also counteract hypertension by lowering blood pressure, as revealed in numerous relevant clinical trials [43,44,45,46]. Here, PPARG is linked to hypertensive disorder.